Regeneron Pharmaceuticals, Inc. (BMV:REGN)
Mexico · Delayed Price · Currency is MXN | Market Cap | 1.13T -2.3% |
| Revenue (ttm) | 268.96B +5.9% |
| Net Income | 79.74B -1.7% |
| EPS | 740.23 +4.1% |
| Shares Out | n/a |
| PE Ratio | 14.23 |
| Forward PE | 12.36 |
| Dividend | 49.77 (0.46%) |
| Ex-Dividend Date | May 20, 2026 |
| Volume | n/a |
| Average Volume | 228 |
| Open | 10,825 |
| Previous Close | 10,825 |
| Day's Range | 10,825 - 10,825 |
| 52-Week Range | 9,420 - 14,276 |
| Beta | n/a |
| RSI | 35.10 |
| Earnings Date | Apr 29, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
Regeneron says EMA accepted review under AA the MAA for Otarmeni
Regeneron (REGN) Pharmaceuticals announced the European Medicines Agency, EMA, has accepted for review under Accelerated Assessment, AA, the Marketing Authorization Application, MAA, for Otarmeni, an ...
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessmen...
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a hematologic complete response (CR) at the highest tested dose Majority of patients with renal or card...
Regeneron price target lowered to $875 from $1,057 at Canaccord
Canaccord analyst John Newman lowered the firm’s price target on Regeneron (REGN) to $875 from $1,057 and keeps a Buy rating on the shares. The firm updated its model following…
Regeneron stock drops double digits on oncology trial failure
Shares of Regeneron Pharmaceuticals (REGN) fell about 12% on Monday, making the biotech company the worst-performing stock in the S&P 500 after its experimental melanoma treatment failed a pivotal lat...
Regeneron price target lowered to $860 from $900 at Wolfe Research
Wolfe Research analyst Alexandria Hammond lowered the firm’s price target on Regeneron (REGN) to $860 from $900 and keeps an Outperform rating on the shares. The company’s LAG-3 trial missed…
Regeneron price target lowered to $825 from $875 at Evercore ISI
Evercore ISI lowered the firm’s price target on Regeneron (REGN) to $825 from $875 and keeps an Outperform rating on the shares. Following the Phase 3 LAG-3 melanoma trial having…
Regeneron price target lowered to $707 from $762 at RBC Capital
RBC Capital lowered the firm’s price target on Regeneron (REGN) to $707 from $762 and keeps a Sector Perform rating on the shares. The company’s Fianlimab miss is a disappointment…
Regeneron price target lowered to $778 from $796 at Truist
Truist lowered the firm’s price target on Regeneron (REGN) to $778 from $796 and keeps a Buy rating on the shares. The firm cites the company’s Phase 3 LAG-3 Fianlimab…
Regeneron price target lowered to $730 from $900 at BMO Capital
BMO Capital lowered the firm’s price target on Regeneron (REGN) to $730 from $900 and keeps an Outperform rating on the shares. The firm notes the company’s Friday’s late night…
Regeneron enters $125M agreement with Parabilis Medicines
Regeneron (REGN) announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates based on Parabilis’ Helicon peptide platform, with a part...
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda
A late-stage trial evaluating Regeneron's fianlimab, a skin cancer drug, fails to meet its primary endpoint.
Regeneron price target lowered to $855 from $875 at Piper Sandler
Piper Sandler lowered the firm’s price target on Regeneron (REGN) to $855 from $875 and keeps an Overweight rating on the shares. The firm notes the company reported topline Phase…
Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints
Shares tumbled premarket after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
The multi-target collaboration combines Regeneron's industry-leading antibody capabilities with Parabilis' novel Helicon™ peptide platform
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines today announced a strategic research collaboration with Regeneron Pharmaceuticals, Inc. to discover and develop multiple therapeutic candidates b...
Regeneron price target lowered to $850 from $950 at JPMorgan
JPMorgan lowered the firm’s price target on Regeneron (REGN) to $850 from $950 and keeps an Overweight rating on the shares. Regeneron reported that its Phase 3 LAG3 melanoma trial…
Leerink cuts Regeneron to Market Perform on LAG-3 failure, Eylea erosion risk
As previously reported, Leerink downgraded Regeneron (REGN) to Market Perform from Outperform with a price target of $641, down from $792. The firm’s three-turn reduction in its price-to-earnings targ...
Regeneron downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Regeneron (REGN) to Market Perform from Outperform with a price target of $641, down from $792.
Regeneron drops after skin cancer treatment misses late-stage trial goal
Shares of Regeneron fell 11.8% premarket on Monday after the company's experimental treatment missed the main goal in a late-stage trial in patients with advanced melanoma, a type of skin cancer.
Regeneron downgraded to Neutral from Buy at Citi
Citi downgraded Regeneron (REGN) to Neutral from Buy with a price target of $700, down from $900. The firm cites the “disappointing” Phase 3 data for fianlimab in metastatic melanoma…
Regeneron announces Phase 3 trial of fianlimab did not reach primary endpoint
Regeneron (REGN) Pharmaceuticals reviewed results from the Phase 3 trial evaluating two dose levels of fianlimab in combination with cemiplimab as a first-line treatment for patients with unresectable...
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the high-...
UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair
TARRYTOWN, N.Y. and WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc., and Society for Science (the Society) announced that Hikaru Kuribayashi , 17, of Sapporo, Japan won th...